Sorafenib is the first multi‐kinase inhibitor (TKI) approved for the treatment of advanced
hepatocellular cancer (HCC) and metastatic renal cell cancer (RCC) and is increasingly …

Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC),
in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC …

Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide
and comes third in cancer-related mortality. Although there is a broad spectrum of treatment …

Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of
cancers. It is currently approved for the treatment of patients with hepatocellular carcinoma …

Aim: Adherence to and the applicability of practice guidelines for the management of
hepatocellular carcinoma (HCC) in field practice have not been fully addressed. We …

The only approved systemic therapy for patients with advanced hepatocellular carcinoma
(HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral …

Aim Patients with hepatocellular carcinoma (HCC) who receive an initial full dose of
sorafenib (800 mg/day) often require a decreased dose (400 mg/day) or discontinuation of …

The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the
vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular …

Aims This prospective pilot study investigated the feasibility of perfusion computed
tomography parameters as surrogate markers of angiogenesis and early response following …

The aims of the present study were to examine whether unresectable hepatocellular
carcinoma (HCC) patients treated with initial dose of sorafenib of 400 mg/day (half‑dose …